Monograph

Baricitinib 2 mg and 4 mg tablets and tofacitinib 5 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

Baricitinib and tofacitinib should be used in line with the clinical criteria in the MAF checklist for initial and continuing prescriptions for patients with rheumatoid arthritis.

Rituximab biosimilar (Truxima) 500 mg concentrate for infusion is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.

SDL subsidy and MAF assistance does not apply to any formulations or strengths of tocilizumab, rituximab reference biologic (MabThera) or other rituximab biosimilars (such as Rixathon).

Truxima 100 mg/10 ml and 500 mg/50 ml concentrate for infusion is recommended for inclusion in the MOH Standard Drug List (SDL) for the abovementioned indications from 18 January 2021. The MAF listing of MabThera will cease on 19 July 2021.

SDL subsidy does not apply to any other rituximab biosimilars (such as Rixathon), or to any formulations or strengths of MabThera.